Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Halozyme Therapeutics Inc shares valued at $500,060 were sold by Henderson Jeffrey William on Jan 06 ’25. At $50.01 per share, Henderson Jeffrey William sold 10,000 shares. The insider’s holdings dropped to 43,611 shares worth approximately $2.34 million following the completion of this transaction.
Also, JEFFREY HENDERSON purchased 10,000 shares, netting a total of over 477,400 in proceeds.
Before that, LaBarre Michael J. had sold 10,000 shares from its account. In a trade valued at $537,469, the SVP, CHIEF TECHNICAL OFFICER traded Halozyme Therapeutics Inc shares for $53.75 each. Upon closing the transaction, the insider’s holdings decreased to 10,000 shares, worth approximately $9.34 million.
As published in a research note from Wells Fargo on October 07, 2024, Halozyme Therapeutics Inc [HALO] has been rated down from an Overweight to an Equal weight and the price target has been revised to $62 from $58. Analysts at JP Morgan downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in mid September. As of June 07, 2024, Piper Sandler has decreased its “an Overweight” rating to a “Neutral” for HALO. Earlier on February 29, 2024, TD Cowen initiated its rating. Their recommendation was “an Outperform” for HALO stock.
Analyzing HALO Stock Performance
During the last five days, there has been a surge of approximately 12.45%. Over the course of the year, Halozyme Therapeutics Inc shares have jumped approximately 12.45%. Shares of the company reached a 52-week high of $55.00 on 01/08/25 and a 52-week low of $47.52 on 01/03/25. A 50-day SMA is recorded $50.32, while a 200-day SMA reached $50.63. Nevertheless, trading volume fell to 2.67 million shares from 1.79 million shares the previous day.
Support And Resistance Levels for Halozyme Therapeutics Inc (HALO)
According to the 24-hour chart, there is a support level at 52.11, which, if violated, would cause prices to drop to 50.47. In the upper region, resistance lies at 55.20. The next price resistance is at 56.65. RSI (Relative Strength Index) is 70.20 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 3.32, which suggests the price will increase in the coming days. Percent R is at 14.19%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
Which companies own the most shares of Halozyme Therapeutics Inc (HALO)?
On July 24, 2023, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $61.
